New Smart Ring Says It Can Deliver Accurate Blood Pressure Tracking Without a Cuff

A new smart ring claims to measure blood pressure without a cuff, calibration, or subscription — a breakthrough in wearable health tech that could challenge traditional monitors. The Vital Signals Signal Ring, priced at $399, uses photoplethysmography (PPG) and machine learning to deliver what the company calls 'cuffless, calibration-free' readings directly from a finger.

Vital Signals, a startup based in the United States, announced the Signal Ring as a direct-to-consumer device aimed at people who want continuous blood pressure tracking without the hassle of inflatable arm cuffs. The ring is available for preorder now, with shipments expected in late 2025. The timing matters: hypertension affects nearly half of U.S. adults, and most existing wearable blood pressure monitors — like the Omron HeartGuide watch — still require periodic cuff calibration. The Signal Ring promises to eliminate that step entirely.

Blood pressure monitoring has traditionally relied on oscillometric cuffs that inflate and deflate, which can be uncomfortable and inconvenient for frequent use. Over the past decade, companies like Apple, Samsung, and Fitbit have explored cuffless methods using optical sensors, but none have yet gained FDA clearance for such readings. The Signal Ring enters a market hungry for a seamless solution. Vital Signals claims its proprietary algorithm analyzes pulse wave velocity from PPG signals and converts them into systolic and diastolic numbers without any user calibration.

Key details: The Signal Ring sells for $399 with no ongoing subscription fees — a differentiator from some rivals that charge monthly for health insights. The ring weighs 6 grams, is water-resistant to 50 meters, and lasts up to seven days on a charge. Vital Signals says it validated the device against a standard cuff in a 50-person study, reporting a mean absolute difference of less than 5 mmHg for both systolic and diastolic readings. The company plans to submit the ring for FDA clearance in 2026. Currently, the device is not FDA-approved and is marketed as a 'wellness' tool rather than a medical device.

Analysis: If the Signal Ring delivers on its accuracy claims, it could reshape how people manage hypertension. The cuffless blood pressure ring eliminates the biggest barrier to regular monitoring: convenience. A ring is less intrusive than a watch or wrist cuff and can be worn 24/7, enabling nighttime readings that traditional cuffs cannot easily capture. However, skepticism remains. Previous attempts at cuffless BP monitoring — from companies like Aktiia — have struggled with long-term accuracy across diverse populations. The absence of FDA clearance also means consumers must trust Vital Signals' internal data. Industry observers note that even if the ring is not a medical device, it could still help users spot trends and encourage them to seek professional diagnosis.

Outlook: The next 12 months are critical for Vital Signals. The company must ship units, gather real-world user data, and ideally secure FDA clearance by 2026. If successful, the Signal Ring could pressure larger players like Apple and Samsung to accelerate their own cuffless blood pressure features. Meanwhile, the broader wearable health market — valued at over $60 billion — watches closely. For now, the promise of a cuffless blood pressure ring is tantalizing, but the proof will be in the pulse.